Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Praxis reported positive regulatory progress on two late-stage assets, with FDA mid-cycle meetings identifying no major safety or efficacy concerns for both ulixacaltamide (PDUFA January 29, 2027) and relutrigine (PDUFA December 27, 2026). FDA BIMO inspections for both programs completed successfully with no Form 483 observations, while the company received its third Breakthrough Therapy Designation for elsunersen in SCN2A DEE. Cash and investments totaled $1.4 billion as of June 30, 2026, providing runway into 2028, following a $447.8 million increase primarily from the January 2026 follow-on offering.
Key figures
- Revenue
- 0
- Drug Name
- ulixacaltamide HCl; relutrigine; elsunersen
- Revenue Yoy
- 0
- Phase Of Trial
- Phase 3 (ulixacaltamide); Phase 3 (relutrigine EMERALD); Phase 2/3 (vormatrigine POWER1 failed); Phase 3 (elsunersen EMBRAVE3)
- Net loss
- 83700000
- Ga expenses
- 27500000
- Rd expenses
- 69400000
- Cash position
- 1400000000
- Cash prior year
- 926100000
- Pdufa relutrigine
- December 27, 2026
- Shares outstanding
- 27900000
- Pdufa ulixacaltamide
- January 29, 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.